Français Japonais Chinois Allemand Néerlandais Espagnol Portugais

    News

    Giroptic makes a splash with Facebook

    At Facebook’s annual conference in California, an enthusiastic Mark Zuckerberg gave a Giroptic iO camera to every attendee—and wrote a $1 million check to the Lille-based start-up.

    Arcelor Mittal Dunkerque investing in performance

    Steelmaker earmarks €31 million for continuous hot mill at Dunkerque plant.

    All news

    GSK to produce two new vaccines at Saint-Amand-les-Eaux site

    21 Sep 2016 | Front page, Health Nutrition, Investment

    For years GSK’s plant in Northern France has worked to raise its profile as one of the pharmaceutical group’s strategic assets. Mission accomplished: two new vaccines will soon be rolling off its production lines, spearheading a drive to conquer the US market by 2018.

    Two new vaccines to be produced at GSK’s Saint-Amand-les-Eaux plant

    Plant in Northern France plays key strategic role

    Since 2015, GlaxoSmithKline (GSK) has invested over €13 million to upgrade production lines and ramp up output at its Saint-Amand-les-Eaux facility, as part of the group’s global strategy. Now Saint-Amand has been selected from among GSK’s 18 sites worldwide to produce new vaccines for shingles and malaria. 

    “This new project show that we’ve become a pacesetter within GSK Group,” says Manufacturing Site Director Géraldine Vetterhoeffer, who has just been named Vice-President Quality for GSK Worldwide.

    The investments point to a bright future for the plant, which is set on conquering the American market by 2018.

    Made in France, exported worldwide

    Nearly 40% of the world’s children are treated with a vaccine made by GSK—an achievement that Ms. Vetterhoeffer readily points out. “My greatest source of pride is that our products have such a powerful impact around the world,” she says. 

    GSK currently exports 70% of the products it makes in France.

    Major investment 

    GSK has operated in Saint-Amand-les-Eaux since 2011, putting a total of €600 million into the plant. That’s the largest industrial investment made by a foreign pharmaceutical company in France over the past 20 years, and it has had huge economic implications for Northern France: the site currently has 800 employees, and sales are expected to rise 20% to 30% in the future. 

    Source: Usine Nouvelle / La Voix du Nord 

    Back to news